SEA-TGT

An investigational sugar-engineered antibody directed to TIGIT



Key Attributes

- Human, nonfucosylated IgG1 monoclonal antibody[1]
- Binds with high affinity to TIGIT and FcγRIIIa with minimal affinity for inhibitory FcγRIIb[1]
- Binding to FcγRIIIa confers enhanced Fc-mediated effector function[1]

Target: TIGIT

- An inhibitory immune checkpoint receptor[2,3]
- Mediates immunosuppressive effects by limiting T cell proliferation and activation[2,3]
- Upregulated in various malignancies, including melanoma, breast cancer, NSCLC, colon cancer, gastric cancer, AML, and MM[3]

Proposed Mechanism of Action[1,4,a]

- Blockade of inhibitory checkpoint signals that binds to T cells
- Depletion of immunosuppressive regulatory T cells
- Amplification of naive and memory T cells

AML: acute myeloid leukemia; **IgG1**: immunoglobulin G1; **MM**: multiple myeloma; **NSCLC**: non-small-cell lung cancer; **TIGIT**: T-cell immunoreceptor with Ig and ITIM domains

[a]Based on preclinical data

1. Smith A et al. AACR virtual 2020: Poster 1583. 2. Chauvin J et al. J Immunother Cancer. 2020: e000957. 3. Harjunpää H et al. Clin Exp Immunol. 2020: 108-19. 4. Smith A et al. SITC virtual 2020: Poster 250.

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

SEA-TGT

Seagen®

Proposed Mechanism of Action[1,2,a]

1. SEA-TGT binds to TIGIT and blocks its interaction with CD155 and CD112, relieving inhibitory signals to T cells
2. Enhanced binding of SEA-TGT to activating FcγRIIIa on innate cells depletes Tregs
3. Selective binding of SEA-TGT to activating FcγRIIIa on APCs upregulates costimulatory molecules and cytokines for T cell activation
4. Activated T cells target and kill tumor cells



APC: antigen-presenting cell; **TIGIT**: T-cell immunoreceptor with Ig and ITIM domains; **Treg**: regulatory T cell

[a]Based on preclinical data

1. Smith A et al. AACR virtual 2020: Poster 1583. 2. Smith A et al. SITC virtual 2020: Poster 250.

Clinical Trials

Phase 1 Phase 2 Phase 3

RECRUITING **SGNTGT-001: Advanced solid tumors and lymphomas** (NCT04254107) SEA-TGT ± sasanlimab

Clinical trial information retrieved from clinicaltrials.gov, accessed Apr 2023.

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Printed in the USA USM/TGT/2023/0002

For more information, contact us at:
+1-855-4SEAGEN (+1-855-473-2436)
medinfo@seagen.com / medinfoEU@seagen.com
www.seagenmedinfo.com